Updated Results of the Safety Run-In of the Phase 3 LOTIS-5 Trial: Novel Combination of Loncastuximab Tesirine With Rituximab (Lonca-R) Versus Immunochemotherapy in Patients With R/R DLBCL-MedSci.cn

Updated Results of the Safety Run-In of the Phase 3 LOTIS-5 Trial: Novel Combination of Loncastuximab Tesirine With Rituximab (Lonca-R) Versus Immunochemotherapy in Patients With R/R DLBCL

Kwiatek, M; Grosicki, S; Jiménez, JL; Mariño, SFP; Snauwaert, S; Kingsley, E; Zacchetti, G; Wang, Y; Wang, LQ; Depaus, J

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023; 23 (): S439

科室
- - 订阅+
  - 更多科室
工具
服务